全部所有文章

United Biomedical Inc. Asia (UBIA) to Receive Royalty Payment of 100 Million RMB derived from FMD Vaccine

United Biomedical Inc. Asia (UBIA) has signed a licensing agreement with Shen Lian Biotechnology (Shanghai) Co. Ltd.  for its UBITh® FMDV-O synthetic peptide vaccine.  With the assistance of United Biomedical, Inc. (UBI), UBIA is to receive approximately 100 million RMB in royalty payment, as well as an annual technology licensing fee with the assistance of United Biomedical, Inc. (UBI). Shen Lian is the largest manufacturer of synthetic peptides in China, located in the Shanghai Zizhu Science Park.

UBITh® FMDV-O synthetic peptide vaccine was developed using UBIA/UBI proprietary designer peptide technology, and was granted first class certification of new veterinary drugs in 2004 in China. UBITh® FMDV-O synthetic peptide vaccine, the first commercialized synthetic peptide vaccine in global market, debuted launched on the market in 2007.Since its debut, over 2 billion doses have been sold. 

The collaboration of UBIA/UBI in development and research, along with Shen Lian’s expertise in sales and marketing, serves to expand the market share of peptide vaccines for swine, and expedite commercialization of UBIA/UBI animal vaccines in China. Such a collaboration will have a profound impact on the cross-strait veterinary market, and will serve as a helpful paradigm for cross strait collaborations in the biotechnology arena.


About UBP (6471)
UBP was established in September 2013 as a spinoff from United Biomedical, Inc., Asia, and is strategically partnering with Formosa Plastics Group. UBP has an integrated monoclonal antibody drug development platform, and focuses on development, manufacturing, and marketing of innovative monoclonal antibody drugs and biosimilars. With a spirit of “innovation and practicality,” UBP is dedicated to addressing unmet medical needs, thereby improving the health of mankind and economic advancement of Taiwan. For more information, please visit https://www.ubpglobal.com/
 
United BioPharma Forward-Looking Statements
The information in this press release should be considered accurate only as of the date of the release. UBP has no intention of updating and specifically disclaims any duty to update the information in this press release. The press release may contain forward-looking statements involving risks and uncertainties and UBP’s actual results may differ materially from those in the forward-looking statements.
回上頁